ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...
Orbital atherectomy has demonstrated clinical advantages compared to historical rotational atherectomy data, including lower rates of target lesion revascularization (TLR) and persistent slow flow/no ...
Subanalysis of procedural events within claudicant, CLI, and renal disease patient populations treated with orbital atherectomy for peripheral arterial disease The CONFIRM series of patients evaluated ...
Apart from higher mortality at 1 year, the 1% of patients who receive rotational atherectomy before PCI have outcomes similar to patients who undergo PCI alone, reports an Australian registry study ...
ST. PAUL, Minn., Cardiovascular Systems, Inc., announced that it has completed enrollment for its Coronary Orbital Atherectomy System Trial (COAST) study. Taking place in both Japan and the United ...
Please provide your email address to receive an email when new articles are posted on . Other tools for interventional cardiologists have come and gone, but atherectomy technology has persisted and — ...
SAN DIEGO, CA — Long-term data with an orbital atherectomy device suggest that approximately one in five patients with severely calcified lesions undergoing PCI will experience a major adverse cardiac ...
Please provide your email address to receive an email when new articles are posted on . In patients undergoing PCI for chronic total occlusion, the use of rotational atherectomy appears to be safe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results